Skip to main content
Year archive

Kintor Pharmaceutical Limited — 2021 filings

All 65 regulatory filings released by Kintor Pharmaceutical Limited (9939) in 2021, sourced directly from the official regulator.

65 Filings
2021 Period
2021 filings (65)
Filing Released Lang
ANNOUNCEMENT INSIDE INFORMATION INTERIM ANALYSIS FOR PHASE III STUDY OF PROXALUTAMIDE FOR PATIENTS WITH MILD TO MODERATE COVID-19 SYMPTOMS
Regulatory Filings
2021-12-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2021
Share Issue/Capital Change
2021-12-01 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information
2021-11-26 English
CHANGE OF JOINT COMPANY SECRETARY AND RESIGNATION OF NON-EXECUTIVE DIRECTOR
Board/Management Information
2021-11-26 English
VOLUNTARY ANNOUNCEMENT PIVOTAL STUDY OF PYRILUTAMIDE FOR TREATMENT OF ANDROGENETIC ALOPECIA MALE PATIENTS RECEIVED CLEARANCE BY CHINA NMPA
Regulatory Filings
2021-11-24 English
VOLUNTARY ANNOUNCEMENT DOSING OF FIRST FEMALE PATIENT IN PHASE II CLINICAL TRIAL OF KX-826 IN CHINA
Regulatory Filings
2021-11-12 English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSING IN TRIAL OF ALK-1 IN COMBINATION WITH KN046 IN ADVANCED OR REFRACTORY SOLID TUMORS
Regulatory Filings
2021-11-02 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2020
Report Publication Announcement
2021-11-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2021
Regulatory Filings
2021-11-01 English
VOLUNTARY ANNOUNCEMENT CHINA NMPA APPROVES CLINICAL TRIAL OF PD-L1/TGF-B DUAL-TARGETING ANTIBODY (GT90008) FOR THE TREATMENT OF ADVANCED SOLID TUMOURS
Regulatory Filings
2021-10-21 English
VOLUNTARY ANNOUNCEMENT CHINA NMPA APPROVES CLINICAL TRIAL OF ALK-1 AND NIVOLUMAB COMBINATION THERAPY FOR THE FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
Regulatory Filings
2021-10-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2021
Regulatory Filings
2021-10-05 English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSING IN US PHASE III CLINICAL TRIAL OF PROXALUTAMIDE FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS
Regulatory Filings
2021-10-04 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information
2021-09-27 English
GRANT OF RESTRICTED SHARE UNITS AND CHANGE OF NON-EXECUTIVE DIRECTOR
Board/Management Information
2021-09-27 English
INTERIM REPORT 2021
Interim / Quarterly Report
2021-09-27 English
VOLUNTARY ANNOUNCEMENT PHASE III CLINICAL TRIAL OF PROXALUTAMIDE FOR THE TREATMENT OF HOSPITALIZED COVID-19 PATIENTS CONDITIONALLY APPROVED BY ANVISA IN BRAZIL
Regulatory Filings
2021-09-26 English
VOLUNTARY ANNOUNCEMENT PHASE II CLINICAL TRIAL OF PYRILUTAMIDE ("KX-826")'S TREATMENT OF AGA IN CHINA REACHED PRIMARY ENDPOINT
Regulatory Filings
2021-09-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021
Share Issue/Capital Change
2021-09-03 English
VOLUNTARY ANNOUNCEMENT KINTOR PHARMA'S TWO PHASE III CLINICAL TRIALS OF PROXALUTAMIDE APPROVED BY NMPA FOR THE PROPOSED TREATMENT OF COVID-19
Regulatory Filings
2021-09-01 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2021
Interim / Quarterly Report
2021-08-27 English
VOLUNTARY ANNOUNCEMENT KINTOR PHARMA COLLABORATES WITH ETANA TO COMMERCIALISE PROXALUTAMIDE FOR THE TREATMENT OF COVID-19 IN INDONESIA
Regulatory Filings
2021-08-25 English
VOLUNTARY ANNOUNCEMENT INCLUSION OF KINTOR AS A CONSTITUENT OF HANG SENG COMPOSITE INDEX
Regulatory Filings
2021-08-20 English
DATE OF BOARD MEETING
Regulatory Filings
2021-08-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2021
Regulatory Filings
2021-08-05 English
VOLUNTARY ANNOUNCEMENT FIRST BATCH SUBJECTS DOSING IN PHASE I CLINICAL TRIAL OF GT20029 (AR-PROTAC) IN CHINA
Regulatory Filings
2021-07-28 English
VOLUNTARY ANNOUNCEMENT KINTOR PHARMACEUTICAL RECEIVED FIRST EMERGENCY USE AUTHORISATION (EUA) FOR PROXALUTAMIDE FOR THE TREATMENT OF COVID-19 IN PARAGUAY
Regulatory Filings
2021-07-16 English
VOLUNTARY ANNOUNCEMENT KINTOR PHARMACEUTICAL COLLABORATES WITH FOSUN PHARMA DEVELOPMENT TO COMMERCIALISE PROXALUTAMIDE FOR THE TREATMENT OF COVID-19 IN INDIA AND AFRICA
Capital/Financing Update
2021-07-15 English
VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG (IND) CLEARANCE BY THE US FDA FOR GT20029 FOR ANDROGENETIC ALOPECIA AND ACNE VULGARIS
Regulatory Filings
2021-07-13 English
VOLUNTARY ANNOUNCEMENT FDA HAS GREENLIGHTED PYRILUTAMIDE (KX-826)'S PHASE II CLINICAL TRIAL FOR ANDROGENETIC ALOPECIA IN THE US
Regulatory Filings
2021-07-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2021
Share Issue/Capital Change
2021-07-02 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information
2021-06-22 English
CHANGE OF NON-EXECUTIVE DIRECTOR
Board/Management Information
2021-06-22 English
VOLUNTARY ANNOUNCEMENT PROXALUTAMIDE'S PIVOTAL STUDY OF TREATING COVID-19 MALE OUTPATIENTS SPONSORED BY KINTOR WAS APPROVED BY ANVISA AND CONEP IN BRAZIL
Regulatory Filings
2021-06-15 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 8 JUNE 2021
Declaration of Voting Results & Voting Rights Announcements
2021-06-08 English
Next Day Disclosure Return
Share Issue/Capital Change
2021-06-02 English
COMPLETION OF TOP-UP PLACING OF EXISTING SHARES AND SUBSCRIPTION FOR SHARES UNDER GENERAL MANDATE
Capital/Financing Update
2021-06-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2021
Share Issue/Capital Change
2021-06-02 English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2020
Environmental & Social Information
2021-05-31 English
(1) TOP-UP PLACING OF EXISTING SHARES (2) SUBSCRIPTION FOR NEW SHARES UNDER GENERAL MANDATE AND (3) SALE OF SHARES BY SELLING SHAREHOLDER
Capital/Financing Update
2021-05-27 English
VOLUNTARY ANNOUNCEMENT (1) FDA HAS GREENLIGHTED PROXALUTAMIDE'S PHASE III CLINICAL TRIAL FOR HOSPITALISED MALE AND FEMALE COVID-19 PATIENTS TO BE CONDUCTED&#x3b; AND (2) INCLUSION OF FEMALE PATIE
Regulatory Filings
2021-05-18 English
VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF TECHNOLOGY OFFICER (CTO) AND APPOINTMENT OF VICE PRESIDENT OF BUSINESS DEVELOPMENT (BD VP)
Board/Management Information
2021-05-16 English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
AGM Information
2021-05-06 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2021-05-06 English
(1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES&#x3b; (2) RE-ELECTION OF RETIRING DIRECTORS&#x3b; (3) RE-APPOINTMENT OF AUDITOR&#x3b; AND (4) NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2021-05-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2021
Share Issue/Capital Change
2021-05-04 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information
2021-04-30 English
RESIGNATION AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND CHANGE OF COMPOSITION OF BOARD COMMITTEE
Board/Management Information
2021-04-30 English
ANNUAL REPORT 2020
Annual Report
2021-04-29 English
VOLUNTARY ANNOUNCEMENT SUCCESSFUL PROXALUTAMIDE COVID-19 PHASE III CLINICAL TRIAL INITIATION AND PATIENT DOSING IN THE UNITED STATES
Regulatory Filings
2021-04-25 English
VOLUNTARY ANNOUNCEMENT SUCCESSFUL DOSING OF THE FIRST BATCH OF PATIENTS FOR ACNE VULGARIS PHASE I/II CLINICAL TRIAL OF PYRILUTAMIDE
Regulatory Filings
2021-04-16 English
VOLUNTARY ANNOUNCEMENT GT20029'S INVESTIGATIONAL NEW DRUG (IND) APPLICATIONS FOR ANDROGENETIC ALOPECIA AND ACNE VULGARIS APPROVED BY CDE OF NMPA
Regulatory Filings
2021-04-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
Capital/Financing Update
2021-04-01 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020&#x3b; CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE&#x3b; WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF TH
Annual Report
2021-03-26 English
DATE OF BOARD MEETING
Regulatory Filings
2021-03-12 English
VOLUNTARY ANNOUNCEMENT RESULTS OF THE CLINICAL TRIAL OF PROXALUTAMIDE FOR THE TREATMENT OF HOSPITALISED COVID-19 PATIENTS
Regulatory Filings
2021-03-11 English
VOLUNTARY ANNOUNCEMENT FDA HAS APPROVED PROXALUTAMIDE'S PHASE III COVID-19 CLINICAL TRIAL
Regulatory Filings
2021-03-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
Capital/Financing Update
2021-03-01 English
VOLUNTARY ANNOUNCEMENT COMPLETION OF RECRUITMENT OF 588 PATIENTS FOR PROXALUTAMIDE'S COVID-19 CLINICAL TRIAL
Regulatory Filings
2021-02-22 English
VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPLICATION OF GT90001'S PHASE II CLINICAL TRIAL FOR ADVANCED HCC APPROVED BY THE US FDA
Regulatory Filings
2021-02-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021
Regulatory Filings
2021-02-02 English
VOLUNTARY ANNOUNCEMENT PROTAC AR DEGRADER GT20029'S INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR ANDROGENETIC ALOPECIA AND ACNE VULGARIS ACCEPTED BY CDE OF NMPA
Regulatory Filings
2021-02-01 English
VOLUNTARY ANNOUNCEMENT CLINICAL TRIAL OF PROXALUTAMIDE FOR THE TREATMENT OF HOSPITALISED COVID-19 PATIENTS APPROVED BY IRB OF BRAZIL
Regulatory Filings
2021-01-28 English
VOLUNTARY ANNOUNCEMENT FINAL RESULTS FOR MALE PATIENTS AND INTERIM RESULTS FOR FEMALE PATIENTS FROM THE CLINICAL TRIAL OF PROXALUTAMIDE FOR THE TREATMENT OF COVID-19
Regulatory Filings
2021-01-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020
Regulatory Filings
2021-01-04 English